Monica L. Guzman

Monica L. Guzman


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
MHMichael Heuser
Michael Heuser
SFSylvie D. Freeman
Sylvie D. Freeman
GOGert J. Ossenkoppele
Gert J. Ossenkoppele
Francesco BuccisanoFrancesco Buccisano
Francesco Buccisano
CHChristopher Hourigan
Christopher Hourigan
JCJacqueline Cloos
Jacqueline Cloos
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.

9 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PDPinkal Desai
Pinkal Desai
NMNuria Mencia-Trinchant
Nuria Mencia-Trinchant
OSOleksandr Savenkov
Oleksandr Savenkov
MSMichael S. Simon
Michael S. Simon
GCGloria Cheang
Gloria Cheang
DHDuane C. Hassane
Duane C. Hassane

25 March 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
VTVicenta Trujillo-Alonso
Vicenta Trujillo-Alonso
EPEdwin C. Pratt
Edwin C. Pratt
HZHongliang Zong
Hongliang Zong
ALAndres Lara-Martinez
Andres Lara-Martinez
CKCharalambos Kaittanis
Charalambos Kaittanis
MGMonica L. Guzman
Monica L. Guzman

5 October 2016 in Nature
Verified
Journal Article
Closed access
PDF file
ARAnna Rodina
Anna Rodina
TWTai Wang
Tai Wang
PYPengrong Yan
Pengrong Yan
EGErica DaGama Gomes
Erica DaGama Gomes
MDMark P. S. Dunphy
Mark P. S. Dunphy
GCGabriela Chiosis
Gabriela Chiosis

6 January 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MMMatthew MacKay
Matthew MacKay
EAEbrahim Afshinnekoo
Ebrahim Afshinnekoo
JRJonathan Rub
Jonathan Rub
CHCiaran Hassan
Ciaran Hassan
MKMihir Khunte
Mihir Khunte
Christopher MasonChristopher Mason
Christopher Mason

17 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SKSzymon Klossowski
Szymon Klossowski
HMHongzhi Miao
Hongzhi Miao
KKKatarzyna Kempinska
Katarzyna Kempinska
TWTao Wu
Tao Wu
TPTrupta Purohit
Trupta Purohit
JGJolanta Grembecka
Jolanta Grembecka
The protein-protein interaction between menin and Mixed Lineage Leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the Nucleophosmin 1 (NPM1) gene. As a step toward clinical translation of menin-MLL1 inhibitors, we report development of MI-3454, a highly potent and orally bioavailable inhibitor of the menin-MLL1 interaction. MI-3454 profoundly inhibited proliferation and induced differentiation in acute leukemia cells and primary patient samples with MLL1 translocations or NPM1 mutations. When applied as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia, including patient-derived xenograft models, through downregulation of key genes involved in leukemogenesis. We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-3454 in leukemia, and demonstrated that this compound is well tolerated and did not impair normal hematopoiesis in mice. Overall, this study demonstrates for the first time profound activity of the menin-MLL1 inhibitor as a single agent in clinically relevant PDX models of leukemia. These data provide a strong rationale for clinical translation of MI-3454 or its analogs for leukemia patients with MLL1-rearrangements or NPM1 mutations